Every 10-Q that Solid Biosciences Inc. (SLDB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SLDB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SLDB filings page.
Solid Biosciences Inc. reported a larger net loss as it advanced its neuromuscular and cardiac gene therapy programs in the quarter ended June 30, 2026. Net loss was $54.8 million for the quarter and $111.5 million for the first half, primarily reflecting higher research and development spending.
Research and development expenses rose to $44.3 million in the quarter and $90.4 million year-to-date, driven by SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich’s ataxia, and SGT-501 for CPVT. General and administrative expenses were $13.1 million for the quarter and $24.3 million for six months.
Cash, cash equivalents and available-for-sale securities totaled $377.7 million as of June 30, 2026, supported by a March 2026 private placement and at-the-market stock sales. The company states it believes this liquidity will fund operating and capital needs into mid-2028.
Solid Biosciences reported a larger quarterly loss as it ramped investment in its gene therapy pipeline. For the three months ended March 31, 2026, net loss was $56.7 million compared with $39.3 million a year earlier, driven mainly by higher research and development spending.
Research and development expenses rose to $46.1 million from $30.9 million, reflecting manufacturing and clinical costs for lead Duchenne candidate SGT‑003 and increased activity in SGT‑212 for Friedreich’s ataxia. General and administrative expenses increased to $11.2 million from $9.1 million.
The company strengthened its balance sheet through a March 2026 private placement and at‑the‑market sales, lifting total assets to $422.9 million and stockholders’ equity to $374.1 million as of March 31, 2026. Cash, cash equivalents and available‑for‑sale securities were $380.7 million, which management expects will fund operations into the first half of 2028.
Solid Biosciences (SLDB) filed its Q3 2025 report, posting a net loss of $45.8 million, driven by higher R&D as clinical programs advanced. R&D was $38.9 million (vs. $27.3 million a year ago) and G&A was $9.2 million (vs. $7.9 million). Total operating expenses reached $48.1 million.
Liquidity remained strong with $236.1 million in cash, cash equivalents and available-for-sale securities as of September 30, 2025, and management indicates funding into the first half of 2027. The company strengthened its balance sheet earlier in the year via the February 2025 offering, yielding approximately $188.0 million in net proceeds and pre-funded warrants. Derivative liabilities tied to FA212 milestones were $6.6 million at quarter-end.
Pipeline updates included progress in SGT-003 (Duchenne), with interim data (as of September 29, 2025) described in the filing, ongoing screening for SGT-212 (FA), and IND/CTA clearances for SGT-501 (CPVT). Shares outstanding were 77,910,239 as of October 29, 2025.
Solid Biosciences Inc. (SLDB) reported expanded clinical progress and a strengthened balance sheet while continuing to record sizable operating losses. As of June 30, 2025 the company held $138.9 million in cash and cash equivalents and $129.2 million in available-for-sale securities, totaling $268.1 million of liquid resources (excluding $1.9 million restricted cash). Total assets were $308.3 million and total liabilities were $50.0 million, leaving stockholders' equity of $258.3 million.
The company posted net losses of $39.5 million and $78.8 million for the three and six months ended June 30, 2025, respectively, driven by research and development spending of $32.4 million and $63.3 million for the same periods. Clinical and regulatory milestones include SGT-003 dosing (15 participants dosed as of August 12, 2025) with reported initial biopsy expression of microdystrophin averaging 110%, SGT-212 IND clearance (Dec 2024), and SGT-501 IND clearance and Health Canada CTA approval (July 2025). The February 2025 offering generated approximately $188.0 million of net proceeds. The company expects its cash, cash equivalents and securities to fund operations into the first half of 2027.